LONG-TERM ENDOCRINE FUNCTION IN HYPERCHOLESTEROLEMIC PATIENTS TREATED WITH PRAVASTATIN, A NEW 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE INHIBITOR

被引:43
作者
DOBS, AS
SARMA, PS
SCHTEINGART, D
机构
[1] JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA
[2] UNIV MICHIGAN, SCH MED, DEPT MED, ANN ARBOR, MI 48104 USA
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 1993年 / 42卷 / 09期
关键词
D O I
10.1016/0026-0495(93)90272-P
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Steroid hormone production within the gonads and adrenals requires a continuous supply of cholesterol derived from de novo synthesis within the gland and from uptake of circulating plasma lipoproteins. Steroid hormone secretion was prospectively studied over 24 months in 64 hypercholesterolemic subjects (group I, aged 52 ± 1 years [mean ± SEM], 61% male) participating in a randomized double-blind clinical trial of pravastatin (20 to 80 mg daily), a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, compared with patients taking cholestyramine or other lipid-lowering drugs (group II). Attempts were made in both groups to maintain serum low-density lipoprotein cholesterol (LDL-C) levels between the 25th and 50th percentile for age and gender. At 24 months, serum LDL-C level decreased by 42% ± 3% in group I and 44% ± 1% in group II (P < .001 v baseline, NS between groups). Basal secretion of cortisol, aldosterone, and dehydroepiandrostenedione sulfate (DHEA-S) was maintained throughout the study. However, the serum DHEA-S secretory response to Cortrosyn (Organon, West Orange, NJ) diminished in both treatment groups at 6 and 12 months (P < .05). In men, basal serum testosterone levels and the testosterone response to human chorionic gonadotropin (HCG) did not change. There was some diminution of sperm motility noted in both treatment groups at 6 and 12 months in the subset of men undergoing semen analysis (n = 14, P < .05). In conclusion, pravastatin had no significant effect on steroid metabolism. Changes noted in DHEA-S were not specific for pravastatin, suggesting that this impairment is related to lipid-lowering effects. © 1993.
引用
收藏
页码:1146 / 1152
页数:7
相关论文
共 24 条
[11]   EFFICACY AND SAFETY OF PRAVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA .1. A DOSE-RESPONSE STUDY [J].
HUNNINGHAKE, DB ;
KNOPP, RH ;
SCHONFELD, G ;
GOLDBERG, AC ;
BROWN, WV ;
SCHAEFER, EJ ;
MARGOLIS, S ;
DOBS, AS ;
MELLIES, MJ ;
INSULL, W ;
STEIN, EA .
ATHEROSCLEROSIS, 1990, 85 (01) :81-89
[12]   HYPOLIPIDEMIC EFFECTS OF HMG-COA REDUCTASE INHIBITORS IN PATIENTS WITH HYPERCHOLESTEROLEMIA [J].
ILLINGWORTH, DR ;
BACON, S .
AMERICAN JOURNAL OF CARDIOLOGY, 1987, 60 (12) :G33-G42
[13]   ADRENAL-CORTICAL FUNCTION IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA [J].
ILLINGWORTH, DR ;
LEES, AM ;
LEES, RS .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1983, 32 (11) :1045-1052
[14]   TISSUE-SELECTIVE INHIBITION OF CHOLESTEROL-SYNTHESIS INVIVO BY PRAVASTATIN SODIUM, A 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE INHIBITOR [J].
KOGA, T ;
SHIMADA, Y ;
KURODA, M ;
TSUJITA, Y ;
HASEGAWA, K ;
YAMAZAKI, M .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1045 (02) :115-120
[15]   REGULATORY ROLE FOR HEPATIC LOW-DENSITY LIPOPROTEIN RECEPTORS INVIVO IN THE DOG [J].
KOVANEN, PT ;
BILHEIMER, DW ;
GOLDSTEIN, JL ;
JARAMILLO, JJ ;
BROWN, MS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (02) :1194-1198
[16]   PRECLINICAL EVALUATION OF LOVASTATIN [J].
MACDONALD, JS ;
GERSON, RJ ;
KORNBRUST, DJ ;
KLOSS, MW ;
PRAHALADA, S ;
BERRY, PH ;
ALBERTS, AW ;
BOKELMAN, DL .
AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (15) :J16-J27
[17]   PLASMA-CORTISOL AND TESTOSTERONE IN HYPERCHOLESTEROLEMIA TREATED WITH CLOFIBRATE AND LOVASTATIN [J].
MASTROBERARDINO, G ;
COSTA, C ;
GAVELLI, MS ;
VITALIANO, E ;
ROSSI, F ;
CATALANO, A ;
BARLETTA, R ;
GUARINI, G .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1989, 17 (04) :388-394
[18]   EFFECTS OF INHIBITION OF CHOLESTEROL-SYNTHESIS BY SIMVASTATIN ON THE PRODUCTION OF ADRENOCORTICAL STEROID-HORMONES AND ACTH [J].
MOL, MJTM ;
STALENHOEF, AFH ;
STUYT, PMJ ;
HERMUS, ARMM ;
DEMACKER, PNM ;
VANTLAAR, A .
CLINICAL ENDOCRINOLOGY, 1989, 31 (06) :679-689
[19]  
MOSLEY ST, 1989, J LIPID RES, V30, P1411
[20]   ROLE OF SERUM-LIPOPROTEINS IN STEROIDOGENESIS BY THE HUMAN-FETAL ADRENAL-CORTEX [J].
SIMPSON, ER ;
CARR, BR ;
PARKER, CR ;
MILEWICH, L ;
PORTER, JC ;
MACDONALD, PC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1979, 49 (01) :146-148